Therapeutic effects of α-iso-cubebenol, a natural compound isolated from the Schisandra chinensis fruit, against sepsis

Biochemical and Biophysical Research Communications

Volumn 427, Issue 3, 2012, Pages 547-552

  Lee, Sung Kyun ^a,b   Kim, Sang Doo ^a   Kook, Minsoo ^a   Lee, Ha Young ^a,b   Park, Joon Seong ^c   Park, Young Hoon ^d   Kang, Jum Soon ^d   Jung, Won Jung ^d   Choi, Young Whan ^d   Bae, Yoe Sik ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Dong A University   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Iso cubebenol; Inflammation; Organ failure; Sepsis

Indexed keywords

ALPHA ISO CUBEBENOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PLANT MEDICINAL PRODUCT; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL VIABILITY; CECUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; FRUIT; IMMUNOCOMPETENT CELL; LIGATION; MALE; MOUSE; NONHUMAN; PERITONEAL FLUID; PRIORITY JOURNAL; PUNCTURE; SCHISANDRA CHINENSIS; SEPSIS; SERUM BACTERICIDAL ACTIVITY; SPLEEN CELL;

ANIMALS; BACTERIA; BIOLOGICAL AGENTS; DISEASE MODELS, ANIMAL; FRUIT; MALE; MICE; MICE, INBRED ICR; SCHISANDRA; SEPSIS; SESQUITERPENES;

MUS; SCHISANDRA CHINENSIS;

EID: 84867862010     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.094     Document Type: Article

References (21)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
3. Kumar G., Kumar N., Taneja A., Kaleekal T., Tarima S., McGinley E., Jimenez E., Mohan A., Khan R.A., Whittle J., Jacobs E., Nanchal R., Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011, 140:1223-1231.
4. Hall M.J., Williams S.N., Defrances C.J., Golosinskiy A. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief 2011, 1-8.
5. Döcke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 1997, 3:678-681.
6. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., et al. Protective effects of C5a blockade in sepsis. Nat. Med. 1999, 5:788-792.
7. + T lymphocytes in humans. J. Immunol. 2001, 166:6952-6963.
8. Wang S.D., Huang K.J., Lin Y.S., Lei H.Y. Sepsis-induced apoptosis of the thymocytes in mice. J. Immunol. 1994, 152:5014-5021.
9. Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 2000, 181:176-180.
10. Reinhart K., Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 2001, 29:S121-S125.
11. Ulloa L., Tracey K.J. The ''cytokine profile'': a code for sepsis. Trends Mol. Med. 2005, 11:56-63.
12. Lee Y.J., Park S.Y., Kim S.G., Park D.J., Kang J.S., Lee S.J., Yoon S., Kim Y.H., Bae Y.S., Choi Y.W. Identification of a novel compound that inhibits iNOS and COX-2 expression in LPS-stimulated macrophages from Schisandra chinensis. Biochem. Biophys. Res. Commun. 2010, 391:1687-1692.
13. Park S.Y., Park D.J., Kim Y.H., Kim Y., Choi Y.W., Lee S.J. Schisandra chinensis α-iso-cubebenol induces heme oxygenase-1 expression through PI3K/Akt and Nrf2 signaling and has anti-inflammatory activity in Porphyromonas gingivalis lipopolysaccharide-stimulated macrophages. Int. Immunopharmacol. 2011, 11:1907-1915.
14. Choi Y.W., Kim H.J., Park S.S., Chung J.H., Lee H.W., Oh S.O., Kim B.S., Kim J.B., Chung H.Y., Yu B.P., Kim C.D., Yoon S. Inhibition of endothelial cell adhesion by the new anti-inflammatory agent alpha-iso-cubebene. Vascul. Pharmacol. 2009, 51:215-224.
15. Kim S.D., Lee H.Y., Shim J.W., Kim H.J., Yoo Y.H., Park J.S., et al. Activation of CXCR2 by extracellular matrix degradation product acetylated Pro-Gly-Pro has therapeutic effects against sepsis. Am. J. Respir. Crit. Care Med. 2011, 184:243-251.
16. Lee H.Y., Jo S.H., Lee C., Baek S.H., Bae Y.S. Differential production of leukotriene B4 or prostaglandin E2 by WKYMVm or serum amyloid A via formyl peptide receptor-like 1. Biochem. Pharmacol. 2006, 72:860-868.
17. Wang J., Silva J.P., Gustafsson C.M., Rustin P., Larsson N.G. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc. Natl. Acad. Sci. USA 2001, 98:4038-4043.
18. Simard J.C., Simon M.M., Tessier P.A., Girard D. Damage-associated molecular pattern S100A9 increases bactericidal activity of human neutrophils by enhancing phagocytosis. J. Immunol. 2011, 186:3622-3631.
19. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants?. J. Leukoc. Biol. 2010, 87:989-999.
20. Guo R.F., Huber-Lang M., Wang X., Sarma V., Padgaonkar V.A., Craig R.A., Riedemann N.C., McClintock S.D., Hlaing T., Shi M.M., Ward P.A. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J. Clin. Invest. 2000, 106:1271-1280.
21. Salomao R., Brunialti M.K., Rapozo M.M., Baggio-Zappia G.L., Galanos C., Freudenberg M. Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock 2012, 38:227-242.